By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site.
Industry: Diagnostics & Research
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Institution %: 96.092
YTD Institution change: 6510998
InsidersInsiders %: 3.751
Insiders Purchases YTD:
Insiders Sales YTD: 56883
Insiders Net YTD: -56883
Analyst RatingsTarget Price: 71.2
Overall Rating: 4.4
Strong Buys (5): 9
Buys (4): 4
Holds (3): 1
Sells (2): 1
Strong Sells (1): 0
52 Week Hi: 63
52 Week Low: 35.02
Beta: 1.179
50 Day MA: 45.4622
200 Day MA: 50.2214
Earnings / Revenue TrendsQtr Earnings Growth YOY: 0
Qtr Revenue Growth YOY: 0.274
Forward PE:
Trailing PE: